TP53 and B-cell chronic lymphocytic leukemia: Notably, even among patients with high-risk genetic markers such as del(17p), TP53 mutations, and unmutated IGHV, those treated with VenR achieved superior outcomes compared to those receiving chemoimmunotherapy, specifically outperforming bendamustine–rituximab in relapsed CLL [32].